Drug Discovery
Researchers Highlight Promising Anticancer Natural Product Synthesis Challenges
A systematic review of heterocyclic natural products reveals significant potential for anticancer drug development while identifying key challenges in synthesizing these compounds efficiently and sustainably.
CNS Pharmaceuticals Secures Orphan Drug Designation for Brain Cancer Treatment
CNS Pharmaceuticals has transferred Orphan Drug Designation for TPI 287, a promising microtubule-stabilizing drug targeting brain cancer and neurological conditions. The designation could provide significant market advantages and potential treatment options for patients with challenging neurological disorders.
Creative Biolabs Showcases AI-Powered Drug Discovery and Innovative Antibody Technology at BioPharma Expo
Creative Biolabs demonstrates technological prowess through an AI-powered drug discovery platform, a global scholarship program for life science students, and a groundbreaking webinar on dual-function antibody technology that could revolutionize cancer treatment.
Quantum BioPharma Advances Multiple Sclerosis Drug Candidate Through Critical Toxicity Studies
Quantum BioPharma has completed key 90-day toxicity studies for its multiple sclerosis drug candidate Lucid-21-302, positioning the company to file an Investigational New Drug application with the FDA and potentially develop a first-in-class MS therapy.
D-Wave and Japan Tobacco Advance Drug Discovery Through Quantum AI
D-Wave Quantum Inc. and Japan Tobacco have successfully completed a quantum computing proof-of-concept project that demonstrates the potential of quantum artificial intelligence in pharmaceutical research, showing improved molecular design capabilities compared to classical methods.
Silexion's Cancer Drug Shows Promise in Precision Oncology Market
Silexion Therapeutics demonstrates significant progress in KRAS-targeted cancer treatment with their RNAi therapeutic SIL-204, positioning the company as a notable player in the rapidly consolidating precision oncology market valued in billions.